<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Drug Assess</journal-id><journal-id journal-id-type="iso-abbrev">J Drug Assess</journal-id><journal-id journal-id-type="publisher-id">IJDA</journal-id><journal-title-group><journal-title>Journal of Drug Assessment</journal-title></journal-title-group><issn pub-type="epub">2155-6660</issn><publisher><publisher-name>Maney Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27536442</article-id><article-id pub-id-type="pmc">4937648</article-id><article-id pub-id-type="publisher-id">ijda-2-87</article-id><article-id pub-id-type="doi">10.3109/21556660.2013.827117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ino</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Terao</surname><given-names>Takumi</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mudd</surname><given-names>Paul N.</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hirama</surname><given-names>Toshiyasu</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label>Medicines Development, Japan Development &#x00026; Medical Affairs Division, GlaxoSmithKline K.K., TokyoJapan</aff><aff id="af2"><label>2</label>Biomedical Data Sciences Department, GlaxoSmithKline K.K., TokyoJapan</aff><aff id="af3"><label>3</label>Clinical Pharmacology, GlaxoSmithKline, Research Triangle Park, NCUSA</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Ms, Hiroko Ino, MPharm, 6-15, Sendagaya 4-chome, Shibuya-ku, Tokyo 151-8566, Japan. Tel.: <phone>+81 3 5786 5078</phone>; Fax: <fax>+81 3 5786 5223</fax>; <email>hiroko.2.ino@gsk.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2013</year></pub-date><volume>2</volume><issue>1</issue><fpage>87</fpage><lpage>93</lpage><history><date date-type="accepted"><day>17</day><month>7</month><year>2013</year><string-date>Accepted on July 17, 2013</string-date></date></history><permissions><copyright-statement>&#x000a9; 2013 The Author(s). Published by Taylor &#x00026; Francis. 2013</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="ijda-2-87.pdf"/><abstract><sec id="S1"><title>Objective</title><p>Fabry disease is a rare X-linked disease caused by mutations to the GLA gene, resulting in a deficiency of the lysosomal enzyme alpha-galactosidase A. This study evaluated the pharmacokinetics, safety, and tolerability of ascending single doses of oral migalastat hydrochloride (HCl), an investigational drug, in healthy Japanese volunteers.</p></sec><sec id="S2"><title>Methods</title><p>In this phase I, randomized, placebo-controlled, single-blind, ascending single-dose, cross-over study, migalastat HCl (50&#x02009;mg, 150&#x02009;mg, or 450&#x02009;mg) or placebo was administered orally to 14 fasting male Japanese volunteers (aged 20&#x02013;55 years) on 4 non-consecutive days. Main plasma and urine pharmacokinetic end-points included maximum observed plasma concentration (<italic>C</italic><sub>max</sub>), time to <italic>C</italic><sub>max</sub> (<italic>t</italic><sub>max</sub>), area under the plasma concentration&#x02013;time curve (AUC), apparent terminal-phase half-life (<italic>t</italic><sub>1/2</sub>), urinary recovery of unchanged drug, renal clearance, and percentage of drug excreted in urine. Safety end-points included adverse events, clinical signs and symptoms (e.g., hematology, chemistry, and urinalysis), vital signs (blood pressure and heart rate), and 12-lead electrocardiogram.</p></sec><sec id="S3"><title>Clinical trial registration number</title><p>ClinicalTrials.gov registration identifier is NCT01853852.</p></sec><sec id="S4"><title>Results</title><p>Median <italic>t</italic><sub>max</sub> of migalastat was 3.0&#x02013;3.5&#x02009;h. Migalastat HCl concentrations declined relatively rapidly, with a mean <italic>t</italic><sub>1/2</sub> of 3.2&#x02013;4.0&#x02009;h. The amount of migalastat HCl recovered in the urine and the percentage of migalastat HCl excreted unchanged over 24&#x02009;h were consistent (&#x0223c;45&#x02013;50%) across the dose range. The AUC and <italic>C</italic><sub>max</sub> of migalastat HCl were dose proportional from 50&#x02013;450&#x02009;mg. Safety results were similar to those observed in non-Japanese populations.</p></sec><sec id="S5"><title>Conclusions</title><p>This study demonstrated that ascending single doses of migalastat HCl (50&#x02009;mg, 150&#x02009;mg, 450&#x02009;mg) are absorbed at a moderate rate and eliminated relatively rapidly, with a safety profile consistent with that observed in non-Japanese populations. These results confirm the dose-proportional pharmacokinetics of migalastat HCl from 50&#x02013;450&#x02009;mg. This study was limited by a small subject population and a short-term follow-up.</p></sec></abstract><kwd-group><kwd>Migalastat HCl</kwd><x xml:space="preserve">, </x><kwd>GR181413</kwd><x xml:space="preserve">, </x><kwd>AT1001</kwd><x xml:space="preserve">, </x><kwd>Pharmacologic chaperone</kwd><x xml:space="preserve">, </x><kwd>Fabry disease</kwd><x xml:space="preserve">, </x><kwd>Pharmacokinetics</kwd><x xml:space="preserve">, </x><kwd>Japanese</kwd></kwd-group></article-meta></front><body><sec id="S6"><title>Introduction</title><p>Fabry disease is a rare X-linked disease caused by mutations to the GLA gene that encodes the lysosomal enzyme alpha-galactosidase A (<italic>&#x003b1;</italic>-Gal A)<xref rid="C1">1</xref>. Some of the mutations generate mutant proteins that do not fold into the correct 3-dimensional (3-D) shape and, therefore, cannot pass through the endoplasmic reticulum for proper trafficking to the lysosomes. Instead, mutant forms of the enzyme are prematurely degraded, resulting in a deficiency of <italic>&#x003b1;</italic>-Gal A activity<xref rid="C2">2</xref>,<xref rid="C3">3</xref>.</p><p>Under normal conditions, <italic>&#x003b1;</italic>-Gal A is involved in the cellular metabolism of the fatty substance globotriaosylceramide (GL-3). A deficiency of <italic>&#x003b1;</italic>-Gal A activity leads to the accumulation of GL-3 in cells and organs throughout the body and, ultimately, to the life-threatening manifestations of Fabry disease: kidney failure, heart disease, and stroke<xref rid="C1">1</xref>,<xref rid="C2">2</xref>,<xref rid="C4">4</xref>.</p><p>The standard of care for Fabry disease is enzyme replacement therapy, which replaces the deficient <italic>&#x003b1;</italic>-Gal A enzyme with regular infusions of recombinant human <italic>&#x003b1;</italic>-Gal A enzyme<xref rid="C5">5</xref>. In contrast, a new oral investigative treatment for Fabry disease, called migalastat hydrochloride (migalastat HCl; GR181413A/AT1001/1-deoxygalactonojirimycin HCl; Amicus Therapeutics, Cranbury, NJ, and GlaxoSmithKline, Research Triangle Park, NC), acts as a pharmacologic chaperone by binding to and stabilizing mutant <italic>&#x003b1;</italic>-Gal A, and allowing the mutant forms of the enzyme to adopt an improved 3-D shape. In doing so, migalastat HCl enables passage of mutant <italic>&#x003b1;</italic>-Gal A into the endoplasmic reticulum for proper cellular trafficking to the lysosomes, where it can now operate in a functionally active state within the lysosome, thereby rectifying the enzyme deficiency to a degree<xref rid="C6 C7 C8 C9 C10">6&#x02013;10</xref>.</p><p>Phase III trials of patients with Fabry disease, including Japanese participants, are currently under way, investigating oral migalastat HCl monotherapy dosed at 150&#x02009;mg every other day (ClinicalTrials.gov identifiers NCT00925301 and NCT01218659). This phase I study (ClinicalTrials.gov identifier: NCT01853852) was the first investigation of migalastat HCl to be conducted in Japanese subjects. The objective was to evaluate the pharmacokinetics, safety, and tolerability of ascending single doses of oral migalastat HCl in healthy Japanese volunteers.</p></sec><sec sec-type="methods" id="S7"><title>Patients and methods</title><sec id="S0007-S2001" disp-level="2"><title>Study design</title><p>This was a randomized, placebo-controlled, single-blind, ascending single-dose, cross-over study in healthy Japanese volunteers. Migalastat HCl or placebo was administered orally to volunteers on 4 different days separated by at least 7 days. As shown in the dosing schedule (<xref ref-type="table" rid="TB1">Table 1</xref>), on 3 of the 4 dosing days, volunteers received a 50-mg, 150-mg, or 450-mg dose in ascending order in the fasted state. Volunteers were randomly allocated to one of four dosing sequences differentiated by what day placebo was given. This study was conducted in line with the 2008 Declaration of Helsinki, Good Clinical Practice principles, and applicable regulatory requirements at the GlaxoSmithKline Medicines Research Unit in Prince of Wales Hospital, Randwick, Australia. Informed consent was obtained from the participants prior to study start. The study protocol and relevant documents were reviewed and approved by the Bellbery Human Research Ethics Committee in Dulwich, South Australia.</p><table-wrap id="TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Planned subject number and dosing schedules.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Sequence</th><th align="center" rowspan="1" colspan="1"><italic>n</italic></th><th align="center" rowspan="1" colspan="1">Dose 1</th><th align="center" rowspan="1" colspan="1">Dose 2</th><th align="center" rowspan="1" colspan="1">Dose 3</th><th align="center" rowspan="1" colspan="1">Dose 4</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">A</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">50&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">150&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">450&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">Placebo</td></tr><tr><td rowspan="1" colspan="1">B</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">50&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">150&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">450&#x02009;mg migalastat HCl</td></tr><tr><td rowspan="1" colspan="1">C</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">50&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">150&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">450&#x02009;mg migalastat HCl</td></tr><tr><td rowspan="1" colspan="1">D</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Placebo</td><td rowspan="1" colspan="1">50&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">150&#x02009;mg migalastat HCl</td><td rowspan="1" colspan="1">450&#x02009;mg migalastat HCl</td></tr></tbody></table><table-wrap-foot><fn><p>HCl, hydrochloride.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0007-S2002" disp-level="2"><title>Subjects</title><p>This trial enrolled healthy Japanese volunteers. &#x02018;Japanese&#x02019; was defined as being born in Japan, having four ethnic Japanese grandparents, holding a Japanese passport or identity papers, and having the ability to speak Japanese, in addition to not living outside of Japan for more than 10 years. Criteria for inclusion were male or female sex, aged between 20&#x02013;55 years, body weight &#x02265;50&#x02009;kg, and body mass index between 18.5&#x02013;29.0&#x02009;kg/m<sup>2</sup>. Women of non-childbearing potential were eligible. Exclusion criteria included positive pre-study results within 3 months of screening for the following conditions: hepatitis B, hepatitis C, or human immunodeficiency virus; positive pre-study results for an alcohol/drug screen; regular use of alcohol and/or tobacco within 6 months of study start; exposure to four new chemical entities within 1 year prior to first study dose; and use of an investigational product in a clinical trial, or use of prescription and non-prescription drugs, within 7 days or 5 half-lives of the first study dose. Women who were pregnant or lactating were ineligible. Participants were permitted to take paracetamol (&#x02264;2&#x02009;g daily).</p></sec><sec id="S0007-S2003" disp-level="2"><title>Procedures</title><p>Blood samples of 2&#x02009;mL for measuring plasma concentrations of migalastat were collected into a tube containing the anticoagulant EDTA-3K prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24&#x02009;h post-dose. Blood samples were mixed thoroughly and kept on crushed ice until the samples were centrifuged at &#x0223c;1500&#x02009;&#x000d7;&#x02009;<italic>g</italic> for 15&#x02009;min to obtain plasma. Plasma samples were prepared within 1&#x02009;h of collection and stored at &#x02212;20&#x000b0;C until analysis.</p><p>Urine samples were collected prior to dosing and at 0&#x02013;4&#x02009;h, 4&#x02013;8&#x02009;h, 8&#x02013;12&#x02009;h, and 12&#x02013;24&#x02009;h after dosing. Urine samples were refrigerated at 2&#x02013;8&#x000b0;C immediately after collection, divided into 1-mL aliquots, and stored at &#x02212;20&#x000b0;C until analysis.</p><p>Concentrations of migalastat in plasma and urine were determined using validated liquid chromatography-tandem mass spectroscopy methods developed by Celerion (Lincoln, NE). The analytical ranges for migalastat were 5.88&#x02013;2940&#x02009;ng/mL in plasma and 100&#x02013;5000&#x02009;ng/mL in urine.</p></sec><sec id="S0007-S2004" disp-level="2"><title>Study drug</title><p>Migalastat HCl is a low molecular weight iminosugar, an analog of the terminal galactose group that is cleaved from the substrate GL-3 (<xref rid="F0001">Figure 1</xref>). Migalastat HCl is being codeveloped by Amicus Therapeutics (Cranbury, NJ) and GlaxoSmithKline (Research Triangle Park, NC). The dosage forms used in this phase I trial were capsules (150&#x02009;mg and 450&#x02009;mg) and oral solution (50&#x02009;mg). Matching placebo was used in capsule form and oral solution.</p><fig id="F0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Chemical structure of migalastat hydrochloride (GR181413A/AT1001)/1-deoxygalactonojirimycin hydrochloride).</p></caption><graphic xlink:href="ijda-2-87.01"/></fig></sec><sec id="S0007-S2005" disp-level="2"><title>Pharmacokinetic parameter assessments</title><p>Each pharmacokinetic parameter for migalastat was calculated by non-compartmental methods using version 4.1 of the software program WinNonlin (Pharsight, St Louis, MO). Plasma concentration&#x02013;time data for migalastat were used to calculate the following parameters: maximum observed plasma concentration (<italic>C</italic><sub>max</sub>), time to <italic>C</italic><sub>max</sub> (<italic>t</italic><sub>max</sub>), last time of quantifiable concentration, terminal-phase rate constant, area under the plasma concentration&#x02013;time curve [AUC<sub>(0&#x02013;</sub><italic><sub>t</sub></italic><sub>)</sub> and AUC<sub>(0&#x02013;&#x0221e;)</sub>], percentage of AUC<sub>(0&#x02013;&#x0221e;)</sub> obtained by extrapolation, apparent terminal-phase half-life (<italic>t</italic><sub>1/2</sub>), apparent clearance following oral dosing, and apparent volume of distribution based on terminal phase. The urine concentration&#x02013;time data of migalastat were used to calculate urinary recovery of unchanged drug, renal clearance, and percentage of the drug excreted in urine.</p></sec><sec id="S0007-S2006" disp-level="2"><title>Safety and tolerability assessments</title><p>Participants underwent the following assessments at screening, the day before and after each dose, and at the follow-up visit (7&#x02013;10 days after the last dose): vital signs (diastolic and systolic blood pressure, heart rate, and body temperature); clinical laboratory tests (i.e., clinical chemistry, hematology, and urinalysis); adverse events (AEs) and serious AEs (SAEs); and 12-lead electrocardiogram (ECG). Subjects received a complete physical examination up to 28 days prior to study start, and a brief physical examination 2 hours prior to dosing and at the follow-up visit.</p></sec><sec id="S0007-S2007" disp-level="2"><title>Statistical analyses</title><p>Summary statistics (<italic>n</italic>, mean [95% confidence interval (CI)], standard deviation [SD], minimum, median, maximum, geometric mean [95% CI], SD on log-scale, and between-subject coefficient of variation [CV]) were derived for each pharmacokinetic parameter per dose. Derived plasma and urine pharmacokinetic parameters were plotted graphically for each dose to demonstrate the pharmacokinetic&#x02013;dose relationship. Dose proportionality for pharmacokinetic parameters of migalastat was analyzed using AUC and <italic>C</italic><sub>max</sub>, and the following power model with 90% CI: log (pharmacokinetic parameter)&#x02009;=&#x02009;&#x003bc;&#x02009;+&#x02009;<italic>S<sub>i</sub></italic>&#x02009;+&#x02009;<italic>P<sub>j</sub></italic>&#x02009;+&#x02009;<italic>&#x003b2;</italic>*log(<italic>D<sub>k</sub></italic>)&#x02009;+&#x02009;<italic>&#x003b5;<sub>ijk</sub></italic>, where &#x003bc; is the overall mean, <italic>S<sub>i</sub></italic> is the random effect for subject <italic>i</italic> following normal distribution <italic>N</italic>(0, <inline-formula><inline-graphic xlink:href="ijda-2-87.IM1.jpg"/></inline-formula>), <italic>P<sub>j</sub></italic> is the fixed period effect, <italic>&#x003b2;</italic> is the slope of log<sub>e</sub>-transformed dose, <italic>D<sub>k</sub></italic> is the dose, and <italic>&#x003b5;<sub>ijk</sub></italic> is the random error following normal distribution <italic>N</italic>(0, <inline-formula><inline-graphic xlink:href="ijda-2-87.IM2.jpg"/></inline-formula>).</p></sec></sec><sec id="S8"><title>Results</title><sec id="S0008-S2001" disp-level="2"><title>Subject characteristics and demographics</title><p>Fourteen volunteers were enrolled and 13 completed the study (<xref ref-type="table" rid="TB2">Table 2</xref>). One subject withdrew consent because of personal reasons, after receiving the 50-mg dose. All the volunteers were Japanese males, with a mean (SD) age of 28 (5) years (range&#x02009;=&#x02009;22&#x02013;38 years) and a mean (SD) body weight of 64 (8) kg (range&#x02009;=&#x02009;54&#x02013;89&#x02009;kg).</p><table-wrap id="TB2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Subject demographics and baseline characteristics.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1"><italic>n</italic></th><th align="center" rowspan="1" colspan="1">Mean (SD)</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Range</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">28.4 (4.89)</td><td rowspan="1" colspan="1">27.5</td><td rowspan="1" colspan="1">22&#x02013;38</td></tr><tr><td rowspan="1" colspan="1">Height (cm)</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">170.1 (5.08)</td><td rowspan="1" colspan="1">170.0</td><td rowspan="1" colspan="1">163&#x02013;178</td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">63.54 (8.456)</td><td rowspan="1" colspan="1">61.05</td><td rowspan="1" colspan="1">53.9&#x02013;89.0</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">21.96 (2.702)</td><td rowspan="1" colspan="1">21.10</td><td rowspan="1" colspan="1">19.4&#x02013;28.4</td></tr></tbody></table><table-wrap-foot><fn><p>BMI, body mass index; NA, not applicable; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0008-S2002" disp-level="2"><title>Single-dose pharmacokinetics of migalastat HCl</title><p><xref rid="F0002">Figure 2</xref> presents the mean plasma concentration&#x02013;time profiles of migalastat in the fasting state. The mean pharmacokinetic parameters of migalastat are summarized in <xref ref-type="table" rid="TB3">Table 3</xref>. Migalastat HCl (50&#x02009;mg, 150&#x02009;mg, and 450&#x02009;mg) was absorbed at a moderate rate following ascending single-dose oral administration, reaching median <italic>t</italic><sub>max</sub> within 3.0&#x02013;3.5&#x02009;h post-dose in the fasted state. These concentrations then declined relatively rapidly, with a mean <italic>t</italic><sub>1/2</sub> of between 3.2&#x02013;4.0&#x02009;h. Migalastat clearance (&#x0223c;13&#x02013;15&#x02009;L/h) and the percentage of migalastat HCl excreted in urine unchanged over 24&#x02009;h (&#x0223c;45&#x02013;50%) were generally consistent across the dose range of 50&#x02013;450&#x02009;mg and, therefore, suggest dose proportionality (<xref ref-type="table" rid="TB3">Table 3</xref>).</p><fig id="F0002" fig-type="figure" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Mean (standard deviation) plasma concentration-time profiles of migalastat hydrochloride after single oral 50-, 150-, and 450-mg doses in healthy male Japanese volunteers in the fasted state. LoQ, limit of quantification.</p></caption><graphic xlink:href="ijda-2-87.02"/></fig><table-wrap id="TB3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Summarized pharmacokinetic parameters of migalastat hydrochloride following single oral 50-, 150-, and 450-mg doses in healthy male Japanese volunteers in the fasted state.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Dose</th><th align="center" rowspan="1" colspan="1"><italic>n</italic></th><th align="center" colspan="9" rowspan="1">Pharmacokinetic parameter</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>C</italic><sub>max</sub> (ng/mL)</th><th align="center" rowspan="1" colspan="1"><italic>t</italic><sub>max</sub>* (h)</th><th align="center" rowspan="1" colspan="1">AUC<sub>(0&#x02013;</sub><italic><sub>t</sub></italic><sub>)</sub> (h&#x000b7;ng/mL)</th><th align="center" rowspan="1" colspan="1">AUC<sub>(0&#x02013;&#x0221e;)</sub> (h&#x000b7;ng/mL)</th><th align="center" rowspan="1" colspan="1"><italic>t</italic><sub>1/2</sub> (h)</th><th align="center" rowspan="1" colspan="1">CL/F (L/h)</th><th align="center" rowspan="1" colspan="1">Ae<sub>(0&#x02013;24)</sub> (mg)</th><th align="center" rowspan="1" colspan="1">CLr (L/h)</th><th align="center" rowspan="1" colspan="1">%FX<sub>(0&#x02013;24)</sub> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">50&#x02009;mg</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">695.1 (36)</td><td rowspan="1" colspan="1">&#x02003;3 (1.5&#x02013;5)&#x02009;</td><td rowspan="1" colspan="1">3,905.4 (35)</td><td rowspan="1" colspan="1">3,961.5 (34.6)</td><td rowspan="1" colspan="1">3.176 (22.5)</td><td rowspan="1" colspan="1">12.621 (34.6)</td><td rowspan="1" colspan="1">24.84 (24.6)</td><td rowspan="1" colspan="1">6.303 (20.6)</td><td rowspan="1" colspan="1">49.67 (24.6)</td></tr><tr><td rowspan="1" colspan="1">150&#x02009;mg</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">2124.3 (36.3)</td><td rowspan="1" colspan="1">3.5 (2&#x02013;5)</td><td rowspan="1" colspan="1">11,430.7 (27.4)</td><td rowspan="1" colspan="1">11,519.4 (27.4)</td><td rowspan="1" colspan="1">3.816 (6.6)</td><td rowspan="1" colspan="1">13.022 (27.4)</td><td rowspan="1" colspan="1">69.97 (22.9)</td><td rowspan="1" colspan="1">6.121 (17.8)</td><td rowspan="1" colspan="1">46.65 (22.9)</td></tr><tr><td rowspan="1" colspan="1">450&#x02009;mg</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">5694.9 (40.4)</td><td rowspan="1" colspan="1">3.5 (2.5&#x02013;5)</td><td rowspan="1" colspan="1">30,453.9 (34.2)</td><td rowspan="1" colspan="1">30,721.7 (34.1)</td><td rowspan="1" colspan="1">4.009 (5.6)</td><td rowspan="1" colspan="1">14.648 (34.1)</td><td rowspan="1" colspan="1">200.43 (20.1)</td><td rowspan="1" colspan="1">6.008 (16)</td><td rowspan="1" colspan="1">44.54 (20.1)</td></tr></tbody></table><table-wrap-foot><fn><p>Geometric mean presented with between-subject coefficient of variation.</p><p>*Arithmetic median (range).</p><p>%Fx<sub>(0&#x02013;24)</sub>, percentage of the drug excreted in urine over 24&#x02009;h; Ae<sub>(0&#x02013;24)</sub>, urinary recovery of unchanged drug over 24&#x02009;h; AUC<sub>(0&#x02013;&#x0221e;)</sub>, area under the concentration&#x02013;time curve from time zero (pre-dose) extrapolated to infinite time; AUC<sub>(0&#x02013;</sub><italic><sub>t</sub></italic><sub>)</sub>, area under the concentration&#x02013;time curve from time zero (pre-dose) to last time of quantifiable concentration; CL/F, apparent clearance following oral dosing; CLr, renal clearance; <italic>C</italic><sub>max</sub>, maximum observed plasma concentration; <italic>t</italic><sub>1/2</sub>, apparent terminal-phase half-life; <italic>t</italic><sub>max</sub>, time to <italic>C</italic><sub>max</sub>.</p></fn></table-wrap-foot></table-wrap><p>The relationship between a dose of migalastat HCl (50&#x02009;mg, 150&#x02009;mg, and 450&#x02009;mg) and <italic>C</italic><sub>max</sub> and AUC is shown in <xref rid="F0003">Figure 3</xref>, with consistent increases in each pharmacokinetic parameter suggesting a dose-proportional association. The confidence intervals around slope contained 1 for each parameter, again suggesting dose-proportionality: <italic>C</italic><sub>max</sub>, 0.95 (90% CI&#x02009;=&#x02009;0.77, 1.14); AUC<sub>(0&#x02013;</sub><italic><sub>t</sub></italic><sub>)</sub>, 1.09 (90% CI&#x02009;=&#x02009;0.92, 1.27); and AUC<sub>(0&#x02013;&#x0221e;)</sub>, 1.09 (90% CI&#x02009;=&#x02009;0.91, 1.26).</p><fig id="F0003" fig-type="figure" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Dose proportionality of (a) <italic>C</italic><sub>max</sub> and (b) AUC<sub>(0&#x02013;&#x0221e;)</sub> following single oral 50-, 150-, and 450-mg doses of migalastat HCl in the fasted state. AUC<sub>(0&#x02013;&#x0221e;)</sub>, area under the concentration--time curve from time zero (predose) extrapolated to infinite time; <italic>C</italic><sub>max</sub>, maximum observed plasma concentration; HCl, hydrochloride; SD, standard deviation.</p></caption><graphic xlink:href="ijda-2-87.03"/></fig></sec><sec id="S0008-S2003" disp-level="2"><title>Safety and tolerability</title><p>No deaths, SAEs, or withdrawals due to AEs were reported as a result of treatment with migalastat HCl. The most common AE was headache, occurring after dosing with placebo (<italic>n&#x02009;=&#x02009;</italic>2), migalastat HCl 50&#x02009;mg (<italic>n&#x02009;=&#x02009;</italic>4), and migalastat HCl 450&#x02009;mg (<italic>n&#x02009;=&#x02009;</italic>2). Treatment-related AEs were reported by six (43%) subjects (<xref ref-type="table" rid="TB4">Table 4</xref>). No correlation emerged between the number or severity of treatment-related AEs and concentrations of migalastat. No migalastat HCl-related clinically significant changes in laboratory values, vital signs, ECG, or physical examination were reported.</p><table-wrap id="TB4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Summary of treatment-related adverse events at each dose level.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="5" rowspan="1">Regimen</th></tr><tr><th align="center" rowspan="1" colspan="1">Adverse event</th><th align="center" rowspan="1" colspan="1">Placebo (<italic>n&#x02009;=&#x02009;</italic>14)</th><th align="center" rowspan="1" colspan="1">50&#x02009;mg (<italic>n&#x02009;=&#x02009;</italic>14)</th><th align="center" rowspan="1" colspan="1">150&#x02009;mg (<italic>n&#x02009;=&#x02009;</italic>13)</th><th align="center" rowspan="1" colspan="1">450&#x02009;mg (<italic>n&#x02009;=&#x02009;</italic>13)</th><th align="center" rowspan="1" colspan="1">Total* (<italic>n&#x02009;=&#x02009;</italic>14)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Any AE</td><td rowspan="1" colspan="1">1 (7)</td><td rowspan="1" colspan="1">4 (29)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (15)</td><td rowspan="1" colspan="1">6 (43)</td></tr><tr><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (21)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (15)</td><td rowspan="1" colspan="1">5 (36)</td></tr><tr><td rowspan="1" colspan="1">Frequent bowel movements</td><td rowspan="1" colspan="1">1 (7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td></tr><tr><td rowspan="1" colspan="1">Seasonal allergy</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td></tr><tr><td rowspan="1" colspan="1">Blood creatinine phosphokinase increased</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td></tr><tr><td rowspan="1" colspan="1">Arthralgia</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (7)</td></tr></tbody></table><table-wrap-foot><fn><p>Data presented as <italic>n</italic> (%).</p><p>*A total number of subjects experiencing AEs from period 1 to period 4.</p><p>AE, adverse event.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="S9"><title>Discussion</title><p>This first-in-Japanese, phase I, randomized, placebo-controlled, cross-over study assessed the pharmacokinetics, safety, and tolerability of ascending single doses of migalastat HCl (50&#x02009;mg, 150&#x02009;mg, and 450&#x02009;mg) in the fasted state. Migalastat exhibited a moderate absorption rate, relatively rapid elimination, and dose-proportional pharmacokinetics. The safety profile seen in this study of healthy Japanese males was consistent with the known safety profile of that in non-Japanese populations<xref rid="C11">11</xref>. Although the pharmacokinetic data presented in this study are precedented by data in non-Japanese subjects, the data are integral to defining the optimal regimen for migalastat HCl in Japanese patients with Fabry disease.</p><p>As with any pharmacokinetics study, potential limitations of this study include the small subject population and the short-term follow-up period. The follow-up period of 7&#x02013;10 days after receipt of the final dose was long enough to characterize the pharmacokinetics of migalastat HCl but might not be sufficient time to detect AEs unrelated to pharmacokinetics. The potential emergence of such AEs should be examined in clinical studies in subjects over a longer treatment period.</p><p>This study corroborates the pharmacokinetic and tolerability findings for migalastat HCl reported in other studies of healthy non-Japanese volunteers<xref rid="C11">11</xref>. In three recent ascending single-dose, phase I, randomized, placebo-controlled clinical trials (FAB-CL-101, FAB-CL-104, and AT1001-010), migalastat HCl (capsules or oral solution) was evaluated in 108 fasting, healthy male and female volunteers (age range&#x02009;=&#x02009;21&#x02013;55 years) in the US<xref rid="C11">11</xref>. Doses in these studies ranged from 25&#x02013;2000&#x02009;mg. Pharmacokinetic findings were similar overall for doses of migalastat HCl ranging from 75&#x02013;1250&#x02009;mg. For example, the mean <italic>C</italic><sub>max</sub> and AUC<sub>0&#x02013;&#x0221e;</sub> values increased in a dose-proportional manner for doses ranging from 75&#x02013;1250&#x02009;mg. However, at the higher doses of 1250&#x02009;mg and 2000&#x02009;mg, mean <italic>C</italic><sub>max</sub> and AUC<sub>0&#x02013;&#x0221e;</sub> were similar and did not increase in a dose-proportional manner. Mean AUC<sub>0&#x02013;</sub><italic><sub>t</sub></italic> and <italic>C</italic><sub>max</sub> values generally increased in a dose-proportional manner between 75&#x02013;675&#x02009;mg. However, AUC values increased more than dose proportionally between 25&#x02013;75&#x02009;mg, likely due to the fact that the terminal elimination profile was not easily assessed at the lower 25-mg dose. Mean <italic>C</italic><sub>max</sub> values generally increased proportionally over the 25&#x02013;675-mg dose range.</p><p>The similarities in the pharmacokinetics of migalastat HCl in Japanese and non-Japanese populations were particularly evident for the 150-mg dose, which is the dose being evaluated in phase III trials<xref rid="C11">11</xref>. For example, in study AT1001-010 of healthy non-Japanese volunteers (<italic>n&#x02009;=&#x02009;</italic>51), after single doses of migalastat HCl 150&#x02009;mg, the geometric mean (CV) values of AUC<sub>0&#x02013;&#x0221e;</sub> and <italic>C</italic><sub>max</sub> were comparable with those of the healthy Japanese volunteers in this study (AUC<sub>0&#x02013;&#x0221e;</sub>&#x02009;=&#x02009;10,449 [25] ng&#x000b7;h/mL vs 11,519 [27] ng&#x000b7;h/mL; <italic>C</italic><sub>max</sub>&#x02009;=&#x02009;1635 [27] ng/mL vs 2124 [36] ng/mL, respectively).</p></sec><sec id="S10"><title>Conclusion</title><p>This phase I study demonstrated that ascending single doses of migalastat HCl (50&#x02009;mg, 150&#x02009;mg, and 450&#x02009;mg), given to healthy Japanese males in the fasted state, are absorbed at a moderate rate, are relatively rapidly eliminated, and demonstrate a safety profile consistent with that of non-Japanese populations. The study also confirmed the dose-proportional pharmacokinetics of migalastat HCl from 50&#x02013;450&#x02009;mg.</p></sec><sec id="S11"><title>Transparency</title><sec id="s11a"><title>Declaration of funding</title><p>This study and its publication were funded by GlaxoSmithKline, Research Triangle Park, NC, and Amicus Therapeutics, Cranbury, NJ.</p></sec><sec id="s11b"><title>Declaration of financial/other relationships</title><p>PNM Jr is employed by GlaxoSmithKline, USA, and holds stock in the company. HI, NT, TT, and TH are employed by GlaxoSmithKline K.K., Japan. TH holds stock in the company. None of the other Japanese authors hold stocks in the company.</p></sec></sec><sec id="S12"><title>Acknowledgments</title><p>The authors would like to thank Jennifer Yuan, MD, PhD, and Paul S. Thomas, MD, PhD (study investigators), and study volunteers for their participation, as well as Franziska Loehrer, PhD, MRQA, Cheryl Friend, and the staff at GlaxoSmithKline Medicines Research Unit in Sydney, Australia, for support in conducting the study. Professional medical writing and editorial assistance was provided by Stephanie Finucane, MS, CMPP of Caudex Medical, New York, and was funded by Amicus Therapeutics and GlaxoSmithKline.</p></sec></body><back><ref-list><title>References</title><ref id="C1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Desnick</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Ioannou</surname><given-names>YA</given-names></name><name name-style="western"><surname>Eng</surname><given-names>CM</given-names></name></person-group>
<article-title>Alpha-galactosidase A deficiency: Fabry disease</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Scriver</surname><given-names>CR</given-names></name><name name-style="western"><surname>Beaudet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Sly</surname><given-names>WS</given-names></name> et al</person-group>, eds. <source>The metabolic and molecular bases of inherited disease</source>. <edition>8th</edition> edn. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>McGraw Hill</publisher-name>, <year>2001</year> p <fpage>3733</fpage>-<lpage>74</lpage></mixed-citation></ref><ref id="C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brady</surname><given-names>RO</given-names></name><name name-style="western"><surname>Gal</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>RM</given-names></name> et al</person-group>
<article-title>Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency</article-title>. <source>N Engl J Med</source>
<year>1967</year>;<volume>276</volume>:<fpage>1163</fpage>-<lpage>7</lpage><pub-id pub-id-type="pmid">6023233</pub-id></mixed-citation></ref><ref id="C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>E</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A</given-names></name><name name-style="western"><surname>Gal</surname><given-names>A</given-names></name></person-group>
<article-title>Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey</article-title>. <source>Acta Paediatr Suppl</source>
<year>2005</year>;<volume>94</volume>:<fpage>87</fpage>-<lpage>92</lpage>; <comment>discussion 79</comment><pub-id pub-id-type="pmid">15895718</pub-id></mixed-citation></ref><ref id="C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kint</surname><given-names>JA</given-names></name></person-group>
<article-title>The enzyme defect in Fabry's disease</article-title>. <source>Nature</source>
<year>1970</year>;<volume>227</volume>:<fpage>1173</fpage><pub-id pub-id-type="pmid">5451124</pub-id></mixed-citation></ref><ref id="C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eng</surname><given-names>CM</given-names></name><name name-style="western"><surname>Germain</surname><given-names>DP</given-names></name><name name-style="western"><surname>Banikazemi</surname><given-names>M</given-names></name> et al</person-group>
<article-title>Fabry disease: guidelines for the evaluation and management of multi-organ system involvement</article-title>. <source>Genet Med</source>
<year>2006</year>;<volume>8</volume>:<fpage>539</fpage>-<lpage>48</lpage><pub-id pub-id-type="pmid">16980809</pub-id></mixed-citation></ref><ref id="C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamin</surname><given-names>ER</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>A</given-names></name> et al</person-group>
<article-title>The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines</article-title>. <source>J Inherit Metab Dis</source>
<year>2009</year>;<volume>32</volume>:<fpage>424</fpage>-<lpage>40</lpage><pub-id pub-id-type="pmid">19387866</pub-id></mixed-citation></ref><ref id="C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>S</given-names></name><name name-style="western"><surname>Asano</surname><given-names>N</given-names></name> et al</person-group>
<article-title>Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor</article-title>. <source>Nat Med</source>
<year>1999</year>;<volume>5</volume>:<fpage>112</fpage>-<lpage>5</lpage><pub-id pub-id-type="pmid">9883849</pub-id></mixed-citation></ref><ref id="C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>JQ</given-names></name></person-group>
<article-title>A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity</article-title>. <source>Trends Pharmacol Sci</source>
<year>2003</year>;<volume>24</volume>:<fpage>355</fpage>-<lpage>60</lpage><pub-id pub-id-type="pmid">12871668</pub-id></mixed-citation></ref><ref id="C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yam</surname><given-names>GH</given-names></name><name name-style="western"><surname>Bosshard</surname><given-names>N</given-names></name><name name-style="western"><surname>Zuber</surname><given-names>C</given-names></name> et al</person-group>
<article-title>Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants</article-title>. <source>Am J Physiol Cell Physiol</source>
<year>2006</year>;<volume>290</volume>:<fpage>C1076</fpage>-<lpage>82</lpage><pub-id pub-id-type="pmid">16531566</pub-id></mixed-citation></ref><ref id="C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yam</surname><given-names>GH</given-names></name><name name-style="western"><surname>Zuber</surname><given-names>C</given-names></name><name name-style="western"><surname>Roth</surname><given-names>J</given-names></name></person-group>
<article-title>A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder</article-title>. <source>FASEB J</source>
<year>2005</year>;<volume>19</volume>:<fpage>12</fpage>-<lpage>18</lpage><pub-id pub-id-type="pmid">15629890</pub-id></mixed-citation></ref><ref id="C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>FK</given-names></name><name name-style="western"><surname>Mudd</surname><given-names>PN</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Bragat</surname><given-names>A</given-names></name> et al</person-group>
<article-title>Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers</article-title>. <source>Clin Pharmacol Drug Dev</source>
<year>2013</year>;<volume>2</volume>:<fpage>120</fpage>-<lpage>32</lpage><pub-id pub-id-type="pmid">27121667</pub-id></mixed-citation></ref></ref-list></back></article>